Nov 24, 2020
This TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc)
Aug 24, 2020
Mellalta Meets conducted a survey in the United States to understand doctors' and KOL's concerns and opinion regarding the impact of recent ACIP guidelines on Pneumococcal Vaccine prescriptions (Prevnar 13 and Pneumovax 23) What is answered! • Changing...
Aug 21, 2020
Market adoption of gene therapy in haemophilia A is still a cause for concern due to the expected high prices, durability issues, redosing, safety concerns and key unknown factors that are still under discussion.
Aug 11, 2020
Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology.
Aug 11, 2020
Karyopharm's Selinexor (Xpovio) an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval.
Jul 31, 2020
Daiichi Sankyo unveiled about the collaboration between them and AstraZeneca for antibody drug conjugate, DS-1062. This news has created absolute havoc in the Pharma market.
Jul 24, 2020
Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge.
Jul 22, 2020
Cabaletta and Artisan bio enter into a gene research collaboration.
Jul 14, 2020
Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the phase 1 study of mitapivat (AG-348) in patients with sickle cell anemia.
Jul 10, 2020
Daiichi Sankyo's DS-1062 is a TROP2-directed antibody drug conjugate (ADC), designed using Daiichi Sankyo's proprietary DXd ADC technology with the highest development stage of Phase I.